To read more on this topic click here.
Repurposed cancer drug shows promise for Parkinson’s
Author: Simge Eva DoganPublished: 5 December 2018
Prep: Cook: Serves:
Researchers at the Oxford Parkinson’s Disease Centre, UK, have repurposed an experimental cancer drug – called tasquinimod – as a potential treatment for Parkinson’s.
The study – funded by Parkinson’s UK and published in science journal ‘Cell Stem Cell’ – has been tested on a total of 10 patients so far.
As part of the research, the study grew brain cells from donated skin cell samples of people living with a rare genetic form of Parkinson’s – this process was then repeated on people with a common non-genetic form of the condition. Researchers found that tasquinimod can block HDAC4, a protein that causes Parkinson’s genes to become inactive.
Professor Richard Wade-Martins, co-lead author of the study, said: “We think that switching off these genes in brain cells may play a vital role in the cell damage and death that occurs in Parkinson’s.”
For more information on the latest Parkinson’s research please visit the EPDA website.
Share this story
Martin Wishart: a Parkinson’s-friendly Christmas meal
Serve up a Michelin star feast this ChristmasREAD MORE
Game on: your invite to Parkinson’s football ‘World Cup’
Forget Euro 2016 and the Copa, there’s another tournament in townREAD MORE
Paint relief: “The joy of painting outshines my Parkinson’s symptoms”
Self-taught artist Walter Reynecke on how painting calms his conditionREAD MORE